Sutow W W, Breslow N E, Palmer N F, D'Angio G J, Takashima J
Am J Clin Oncol. 1982 Aug;5(4):339-47. doi: 10.1097/00000421-198208000-00001.
Survival data from the first National Wilms' Tumor Study were analyzed on 101 patients who relapsed after primary therapy (group I-III) and on 82 patients who presented initially with metastases (group IV). The group I patients had significantly better 3-year survival rates than group II/III patients (64% vs 37%). Histology, relapse site, and time to relapse all showed strong independent effects on survival even in the presence of other variables. The survival curves were significantly better for patients with favorable histology, extraabdominal metastases, and late metastases. The overall survival (longer than 3 years) was 46% of group I-III patients who relapsed and 56% of group IV patients.
对来自首个国家肾母细胞瘤研究的生存数据进行了分析,涉及101例初次治疗后复发的患者(I - III组)和82例初诊时即有转移的患者(IV组)。I组患者的3年生存率显著高于II/III组患者(64%对37%)。即使存在其他变量,组织学类型、复发部位和复发时间对生存率均显示出强烈的独立影响。组织学类型良好、腹部外转移和晚期转移患者的生存曲线明显更好。复发的I - III组患者的总生存率(超过3年)为46%,IV组患者为56%。